01
ProblemNeurology infusion teams keep rescuing patients who look booked for the next Ocrevus, Tysabri, Briumvi, or Lemtrada dose but are still blocked by expiring prior auth, site-of-care changes, pharmacy routing failures, or stale documentation.
ProblemNeurology infusion teams keep rescuing patients who look booked for the next Ocrevus, Tysabri, Briumvi, or Lemtrada dose but are still blocked by expiring prior auth, site-of-care changes, pharmacy routing failures, or stale documentation.
SolutionClearDose MS reads payer letters, infusion schedules, and coordinator inboxes, then sorts the next-dose queue into ready, expiring, blocked, and reroute cases with blocker tags such as 12-month reauth due, G35 code mismatch, or white-bagging reset.
Market opportunityMS therapeutics reached $34.80B in 2025, IV infusion represented $9.05B, and neurology EMR budgets already run about $150-$395 per provider per month, leaving room for an $800-$2,000 monthly continuity desk.